Morgan Stanley Catalyst Pharmaceuticals, Inc. Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
A detailed history of Morgan Stanley transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,183,523 shares of CPRX stock, worth $65.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,183,523
Previous 2,394,555
32.95%
Holding current value
$65.5 Million
Previous $58.1 Million
18.97%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding CPRX
# of Institutions
385Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$385 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$180 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$113 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$66.9 Million0.1% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY2.88MShares$59.3 Million1.44% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.12B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...